Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...

Lexicon收到了FDA對Zynquista的完整回覆信；表示這一預期的溝通符合之前披露的戰略決定，即停止Zynquista的上市準備，並專注於其臨牀開發...

Benzinga · 05:34

Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development Pipeline

Lexicon收到了關於Zynquista的完整回覆函；表示這封來自FDA的預期通信與之前披露的戰略決策一致，即停止Zynquista的上市準備，專注於其臨牀開發管道。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。